Prostate international · 2026
Context-dependent role of digital rectal examination in a contemporary prostate biopsy cohort: differential predictive value with and without multiparametric magnetic resonance imaging.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lagos-Beitz Horst E, Borbolla-Ruíz Alexa, González-Sosa Wolfgang, González-Quirós Carlos A, Castillejos-Molina Ricardo A, Alcacio-Mendoza Jorge A, Tena-Gonzalez Mendez Gerardo
Аннотация
OBJECTIVE: To quantify the context-dependent contribution of digital rectal examination (DRE) to the prediction of clinically significant prostate cancer (csPCa, International Society of Urological Pathology [ISUP] grade group ≥2) in a contemporary biopsy cohort, comparing a nonmultiparametric magnetic resonance imaging (mpMRI) clinical pathway with an mpMRI-informed pathway including prostate imaging-reporting and data system (PI-RADS).
MATERIALS AND METHODS: We performed a retrospective analysis of 666 consecutive prostate biopsies at a single academic center (July 2017-December 2024). DRE was performed by urology residents and attending urologists. Two multivariable logistic regression models were constructed: Model A (full cohort, n = 612) included age, log-prostate-specific antigen (PSA), log-PSA density (PSAD), prior biopsy, and DRE; Model B (mpMRI subcohort, N = 306) additionally included PI-RADS score. Discrimination was assessed using area under the curve (AUC) and likelihood ratio tests. Sensitivity analyses evaluated any cancer (ISUP ≥1) and high-grade cancer (ISUP ≥4).
RESULTS: csPCa prevalence was 30.7% (202/660), and DRE was suspicious in 52.3% (346/662). In Model A, DRE was independently associated with csPCa (adjusted odds ratio [aOR], 2.18, 95% confidence interval [CI]: 1.45-3.28, P < 0.001), although the gain in discrimination was modest (ΔAUC = 0.009). In Model B, DRE showed borderline significance (aOR, 1.88, 95% CI: 1.01-3.52, P = 0.048) with negligible discrimination gain (ΔAUC = 0.002). Sensitivity analyses showed consistent findings. A dose-response gradient was observed: csPCa rates were 19.2% (normal), 31.6% (cT2a), and 58.9% (cT2b-T4) (p-trend <0.0001).
CONCLUSIONS: DRE was independently associated with csPCa in the absence of mpMRI, but its incremental discriminative contribution was modest and became negligible once PI-RADS was incorporated. These findings support a limited, context-dependent role for DRE in contemporary biopsy pathways.
MATERIALS AND METHODS: We performed a retrospective analysis of 666 consecutive prostate biopsies at a single academic center (July 2017-December 2024). DRE was performed by urology residents and attending urologists. Two multivariable logistic regression models were constructed: Model A (full cohort, n = 612) included age, log-prostate-specific antigen (PSA), log-PSA density (PSAD), prior biopsy, and DRE; Model B (mpMRI subcohort, N = 306) additionally included PI-RADS score. Discrimination was assessed using area under the curve (AUC) and likelihood ratio tests. Sensitivity analyses evaluated any cancer (ISUP ≥1) and high-grade cancer (ISUP ≥4).
RESULTS: csPCa prevalence was 30.7% (202/660), and DRE was suspicious in 52.3% (346/662). In Model A, DRE was independently associated with csPCa (adjusted odds ratio [aOR], 2.18, 95% confidence interval [CI]: 1.45-3.28, P < 0.001), although the gain in discrimination was modest (ΔAUC = 0.009). In Model B, DRE showed borderline significance (aOR, 1.88, 95% CI: 1.01-3.52, P = 0.048) with negligible discrimination gain (ΔAUC = 0.002). Sensitivity analyses showed consistent findings. A dose-response gradient was observed: csPCa rates were 19.2% (normal), 31.6% (cT2a), and 58.9% (cT2b-T4) (p-trend <0.0001).
CONCLUSIONS: DRE was independently associated with csPCa in the absence of mpMRI, but its incremental discriminative contribution was modest and became negligible once PI-RADS was incorporated. These findings support a limited, context-dependent role for DRE in contemporary biopsy pathways.